Unknown

Dataset Information

0

Advanced neuroendocrine prostate tumors regress to stemness.

ABSTRACT:

SUBMITTER: Ellis L 

PROVIDER: S-EPMC4664372 | biostudies-literature | 2015 Nov

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Advanced neuroendocrine prostate tumors regress to stemness.

Ellis Leigh L   Loda Massimo M  

Proceedings of the National Academy of Sciences of the United States of America 20151117 47

Similar Datasets

Unknown Everolimus for advanced pancreatic neuroendocrine tumors.
| S-EPMC4208619 | biostudies-literature
Unknown Targeted therapy in advanced well-differentiated neuroendocrine tumors.
| S-EPMC3228104 | biostudies-literature
Unknown Treatment Sequencing Strategies in Advanced Neuroendocrine Tumors: A Review.
| S-EPMC9656186 | biostudies-literature
Unknown A phase II study of axitinib in advanced neuroendocrine tumors.
| S-EPMC4963225 | biostudies-literature
Unknown Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors.
| S-EPMC11821447 | biostudies-literature
Unknown Evaluation of Outcomes Following Surgery for Locally Advanced Pancreatic Neuroendocrine Tumors.
| S-EPMC7643030 | biostudies-literature
Unknown Non-Pharmacological Therapeutic Options for Liver Metastases in Advanced Neuroendocrine Tumors.
| S-EPMC6912565 | biostudies-literature
Unknown Multicenter phase 2 trial of nintedanib in advanced nonpancreatic neuroendocrine tumors.
| S-EPMC8396074 | biostudies-literature
Unknown Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors.
| S-EPMC2919332 | biostudies-literature
Unknown Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.
| S-EPMC4874232 | biostudies-literature